Literature DB >> 6133297

A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity.

T P Hogan, A G Awad, R Eastwood.   

Abstract

Schizophrenic patients' self-reports of their experience of neuroleptic treatment were used as the basis for the construction of a scale predictive of drug compliance. Reliability analysis of the responses of 150 patients indicated high internal consistency in the 30-item scale, and preliminary validation in the form of discriminant classification accurately assigned 89% of the sample to complaint and non-compliant groupings. Both discriminant and factor analyses suggest that maximum variability in responding is accounted for by items reflecting how the patient feels on medication, rather than what he knows or believes about medication.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6133297     DOI: 10.1017/s0033291700050182

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  219 in total

Review 1.  Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.

Authors:  A George Awad
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

Review 2.  Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?

Authors:  Azizah Attard; David M Taylor
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

3.  [The initial dysphoric reaction (IDR) to the first dose of neuroleptics].

Authors:  B Graf Schimmelmann; M Schacht; C Perro; M Lambert
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

4.  Effects of a Psychoeducation Program for People with Schizophrenia Aimed at Increasing Subjective Well-Being and the Factors Influencing Those Effects: a Preliminary Study.

Authors:  Ayumi Shinozaki; Teruo Hayashi; Hitoshi Okamura
Journal:  Psychiatr Q       Date:  2020-03

Review 5.  The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.

Authors:  Hwang-Bin Lee; Bo-Hyun Yoon; Young-Joon Kwon; Young Sup Woo; Jung-Goo Lee; Moon-Doo Kim; Won-Myong Bahk
Journal:  Clin Drug Investig       Date:  2013-10       Impact factor: 2.859

Review 6.  Supportive therapy for schizophrenia.

Authors:  Lucy A Buckley; Nicola Maayan; Karla Soares-Weiser; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2015-04-14

7.  Social interaction and drug attitude effectiveness in patients with schizophrenia.

Authors:  Jui-Kang Tsai; Wen-Kuo Lin; For-Wey Lung
Journal:  Psychiatr Q       Date:  2011-12

Review 8.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

9.  Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.

Authors:  Christian G Widschwendter; Georg Kemmler; Maria A Rettenbacher; Nursen Yalcin-Siedentopf; Alex Hofer
Journal:  BMC Psychiatry       Date:  2018-06-28       Impact factor: 3.630

10.  Compliance therapy: a randomised controlled trial in schizophrenia.

Authors:  Colin O'Donnell; Gary Donohoe; Louise Sharkey; Nicholas Owens; Maria Migone; Raewynn Harries; Anthony Kinsella; Conall Larkin; Eadbhard O'Callaghan
Journal:  BMJ       Date:  2003-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.